Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropidoxuridine - Shuttle Pharmaceuticals

Next Previous
Drug Profile

Ropidoxuridine - Shuttle Pharmaceuticals

Alternative Names: 5-Iodo-2-pyrimidinone 2'' deoxyribonucleoside; 5-Iodo-2-pyrimidinone-2''-deoxyribose; IMRT; Intensity Modulated RT; Intensity-Modulated Radiotherapy; IPdR - Shuttle Pharmaceuticals; Ropidoxuridine-Shuttle-Pharmaceuticals

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shuttle Pharmaceuticals
  • Developer National Cancer Institute (USA); Shuttle Pharmaceuticals
  • Class Antineoplastics; Pyrimidine nucleosides; Radiation-sensitising agents; Small molecules
  • Mechanism of Action DNA inhibitors; DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • No development reported Gastrointestinal cancer; Sarcoma

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Metastatic disease) in USA (PO)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Sarcoma in USA (PO)
  • 02 Sep 2024 Phase-II clinical trials in Glioblastoma (First-line therapy) in USA (PO) (NCT06359379)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top